A total of 415 healthy adults 18 years and older are expected to be enrolled in the trial across 13 investigational sites. Participants will receive one dose of MRT5500 or two doses 21 days apart at the dose levels of 15 µg, 45 µg, or 135 µg. Preclinical studies to assess efficacy against emerging SARS-CoV-2 variants will continue for the next several months, according to the firms.

Additionally, a joint development team is working to improve MRT5500's temperature stability, aiming for a -20° C storage temperature for late-stage clinical trials and at the vaccine's launch. The firms are also striving for stability at routine refrigerator temperatures (2° C to 8° C).

Clinical pipeline promises effective 2nd-generation COVID-19 vaccines
Despite the small number of COVID-19 vaccines that have been granted emergency use authorizations by the U.S. Food and Drug Administration to date, many...

Sirion Biotech, Sanofi to improve AAV capsids
Sirion Biotech has signed a license and collaboration agreement with Sanofi to develop improved tissue-selective adeno-associated virus (AAV) vectors...

Sanofi, GSK start phase II COVID-19 vaccine study
Sanofi and GlaxoSmithKline (GSK) are starting a large phase II study of their COVID-19 vaccine.

Curadigm collaborates with Sanofi on combo product to improve gene therapies
Nanobiotix, through its wholly owned subsidiary Curadigm, has signed a new collaboration agreement with Sanofi for the use of its Nanoprimer technology...

Top biopharma companies form data exchange nonprofit
Ten of the world's largest biopharmaceutical companies publicly launched a new nonprofit corporation, Accumulus Synergy. The aim is to support interactions...